RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2023-11-17
What RESPIRERX PHARMACEUTICALS INC. reported in its quarterly report filed 2023-11-17 (fiscal Q3 2023): 24 published measures, 82 facts as tagged in accession 0001493152-23-041875.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-17
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-041875 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All RESPIRERX PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 108,664 | USD | |
| At 2022-12-31 | 22,781 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 12,405,118 | USD | |
| At 2022-12-31 | 11,903,101 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -12,296,454 | USD | |
| At 2023-06-30 | -12,142,352 | USD | |
| At 2023-03-31 | -12,310,383 | USD | |
| At 2022-12-31 | -11,880,320 | USD | |
| At 2022-09-30 | -11,590,629 | USD | |
| At 2022-06-30 | -11,131,459 | USD | |
| At 2022-03-31 | -10,867,921 | USD | |
| At 2021-12-31 | -10,007,758 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 6,362 | USD | |
| At 2022-12-31 | 88 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -395,502 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,506,595 | USD | 273 |
| 2023-04-01 to 2023-06-30 | -681,030 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -430,063 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -472,578 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,813,029 | USD | 273 |
| 2022-04-01 to 2022-06-30 | -480,288 | USD | 91 |
| 2022-01-01 to 2022-03-31 | -860,163 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -258,726 | USD | 273 |
| 2022-01-01 to 2022-12-31 | -143,905 | USD | 365 |
| 2022-01-01 to 2022-09-30 | -155,061 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 265,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 153,723 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -177,564,451 | USD | |
| At 2022-12-31 | -176,057,856 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 267,732,995 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 191,241,348 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 119,264,928 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 107,816,034 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 267,732,995 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 191,241,348 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 119,264,928 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 107,816,034 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.002 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.008 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.014 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.031 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.002 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.008 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.014 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.031 | USD/shares | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -332,509 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,186,886 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -388,966 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,358,393 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 108,664 | USD | |
| At 2022-12-31 | 22,781 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 73,408 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 365,729 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 94,643 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 533,812 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 12,061,118 | USD | |
| At 2022-12-31 | 11,729,101 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 6,627,788 | USD | |
| At 2022-12-31 | 5,724,390 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 332,509 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,186,886 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 388,966 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,358,393 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 87,380 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 284,020 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 138,050 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 400,307 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 298,328,647 | shares | |
| At 2022-12-31 | 125,544,276 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 164,158,537 | USD | |
| At 2022-12-31 | 164,030,289 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -409,169 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,531,022 | USD | 273 |
| 2022-01-01 to 2022-12-31 | -3,972,993 | USD | 365 |
| 2022-07-01 to 2022-09-30 | -1,641,172 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -3,333,361 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 245,129 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 902,866 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 250,916 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 958,086 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 8,222 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 10,308 | USD | 273 |
Inspect the source
- Entity
- RESPIRERX PHARMACEUTICALS INC. / CIK 0000849636
- Captured
- SEC response SHA-256
f692532c7d166963e2fad68da28689f5b935e4c0402c22ccfa62bc8615c926ab
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000849636.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))